Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the primary endpoint was met for the second population in its Phase 2 clinical trial evaluating dazodalibep for the treatment of Sjogren's syndrome.

The Phase 2 trial evaluated two patient populations and positive results in the first patient population were announced in September 2022. Dazodalibep is the only medicine in development to achieve the primary endpoint in both patient populations in a Phase 2 trial.

Today, the Company announced that the second population achieved the primary endpoint. This patient population includes those with moderate-to-severe symptomatology including dryness, pain and fatigue despite lacking additional organ involvement and is defined as patients with a European Alliance of Associations for Rheumatology (EULAR) Sjogren's Syndrome Patient Reported Index (ESSPRI) score of5, indicative of significant symptomatic burden, and a score of

(C) 2023 Electronic News Publishing, source ENP Newswire